Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Conference News ACC 2021

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

Yael L. Maxwell

May 26, 2021

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Conference News ACC 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Yael L. Maxwell

May 17, 2021

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

L.A. McKeown

May 16, 2021

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Caitlin E. Cox

March 17, 2019

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

Presentation ACC 2018

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Presenter: Francesco Franchi

March 11, 2018

Advertisement

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Managing AF Patients Undergoing PCI—Some Lingering Questions

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content